This week's Fierce Biotech Research is brought to you by Lonza.

Hi E, check out this Fierce White Paper we think you'll like:

A focus on cell line development: Accelerating antibody DNA to IND timelines without negatively impacting quality

Novel antibody-based therapeutics have revolutionized healthcare and are a prominent feature on top-selling pharmaceutical lists. As antibody engineering and manufacturing technologies improve, previously untreatable diseases can be targeted with increased speed and efficiency. Creating a pathway that balances cost, speed and risk for therapeutic antibody development is crucial to successful and timely approval of new therapeutics.

In this whitepaper, discover how to:

Keep up with an evolving market
Optimize cell line development workflow
Harness cell pools for accelerated program design

Download Now

You are currently subscribed as newsletter@newslettercollector.com
If you no longer wish to receive promotions from Fierce LifeSciences, simply unsubscribe.
Refer to our Privacy Policy.

Fierce LifeSciences is a division of Questex LLC.
685 3rd Ave 21st Floor New York, NY 10017
© 2023 Questex LLC. All Rights Reserved.
Reproduction in whole or in part is prohibited without written permission.